Related references
Note: Only part of the references are listed.Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial
Christine Katlama et al.
AIDS (2016)
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutierrez et al.
AIDS (2016)
IL-7 Induces SAMHD1 Phosphorylation in CD4+T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle
Mayte Coiras et al.
CELL REPORTS (2016)
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes
R. Brad Jones et al.
PLOS PATHOGENS (2016)
Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal
Marta Martinez-Bonet et al.
ANTIVIRAL RESEARCH (2015)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies
Amanda M. Crooks et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity
Javier Garcia-Perez et al.
RETROVIROLOGY (2015)
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
Marta Martinez-Bonet et al.
SCIENTIFIC REPORTS (2015)
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
Gilles Darcis et al.
PLOS PATHOGENS (2015)
Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
Mario Ostrowski et al.
OPEN FORUM INFECTIOUS DISEASES (2015)
In Vitro Immunological Effects of Blocking CCR5 on T Cells
Jing Yuan et al.
INFLAMMATION (2015)
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection
Maria C. Puertas et al.
AIDS (2014)
Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+T cell recovery and gene expression
Nadejda Beliakova-Bethell et al.
ANTIVIRAL RESEARCH (2014)
HIV-1 persistence in CD4+ T cells with stem cell like properties
Maria J. Buzon et al.
NATURE MEDICINE (2014)
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
C. Korin Bullen et al.
NATURE MEDICINE (2014)
A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence
Michelle Kim et al.
NATURE PROTOCOLS (2014)
Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy
Anthony R. Cillo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Datsen George Wei et al.
PLOS PATHOGENS (2014)
Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
Alain Lafeuillade et al.
AIDS RESEARCH AND THERAPY (2014)
Pharmacokinetics, Safety, and Tolerability of Maraviroc in HIV-Negative Subjects with Impaired Renal Function
Manoli Vourvahis et al.
HIV CLINICAL TRIALS (2013)
In vitro effects of the CCR5 inhibitor maraviroc on human T cell function
H. Arberas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Combined approaches for HIV cure
David M. Margolis et al.
CURRENT OPINION IN HIV AND AIDS (2013)
Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation
Thomas Aagaard Rasmussen et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
24 Hours in the Life of HIV-1 in a T Cell Line
Pejman Mohammadi et al.
PLOS PATHOGENS (2013)
An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+T Cells from Aviremic Patients
Celsa A. Spina et al.
PLOS PATHOGENS (2013)
Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
Susanne Eriksson et al.
PLOS PATHOGENS (2013)
Maraviroc Intensification of Stable Antiviral Therapy in HIV-1-Infected Patients With Poor Immune Restoration: MARIMUNO-ANRS 145 Study
Lise Cuzin et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity
Ildefonso Pulido et al.
JOURNAL OF INFECTION (2012)
New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection
Javier Garcia-Perez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Protein Kinase Cθ Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+ T Lymphocytes
Maria Rosa Lopez-Huertas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Allosteric Model of Maraviroc Binding to CC Chemokine Receptor 5 (CCR5)
Javier Garcia-Perez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells
Alberto Bosque et al.
METHODS (2011)
Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected
Carolina Gutierrez et al.
PLOS ONE (2011)
Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+T cells
Suha Saleh et al.
RETROVIROLOGY (2011)
Homeostatic Proliferation Fails to Efficiently Reactivate HIV-1 Latently Infected Central Memory CD4+T Cells
Alberto Bosque et al.
PLOS PATHOGENS (2011)
Maternal-Fetal Pharmacokinetics and Dynamics of a Single Intrapartum Dose of Maraviroc in Rhesus Macaques
Mark A. Winters et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Moises Perez et al.
CURRENT HIV RESEARCH (2010)
Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
Rajeev Mehla et al.
PLOS ONE (2010)
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients
Nicholas Funderburg et al.
PLOS ONE (2010)
Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton
Paul U. Cameron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection
Irini Sereti et al.
BLOOD (2009)
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
Nicolas Chomont et al.
NATURE MEDICINE (2009)
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Mayte Coiras et al.
NATURE REVIEWS MICROBIOLOGY (2009)
The Challenge of Finding a Cure for HIV Infection
Douglas D. Richman et al.
SCIENCE (2009)
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment
Samantha Abel et al.
ANTIVIRAL THERAPY (2009)
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects
Samantha Abel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latency
Alessandra Marini et al.
JOURNAL OF IMMUNOLOGY (2008)
Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection:: a novel model of HIV-1 latency
Suha Saleh et al.
BLOOD (2007)
Interleukin 7 reduces the levels of spontaneous apoptosis in CD4+ and CD8+ T cells from HIV-1-infected individuals
Lia Vassena et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
P Dorr et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV
DK Walker et al.
DRUG METABOLISM AND DISPOSITION (2005)
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
JD Siliciano et al.
NATURE MEDICINE (2003)
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro
A Jordan et al.
EMBO JOURNAL (2003)
Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype
DD Scripture-Adams et al.
JOURNAL OF VIROLOGY (2002)
Structure modeling of the chemokine receptor CCR5: Implications for ligand binding and selectivity
MG Paterlini
BIOPHYSICAL JOURNAL (2002)
Activation of the MEK/MAPK pathway is involved in bryostatin1-induced monocytic differenciation and up-regulation of X-linked inhibitor of apoptosis protein
H Lin et al.
EXPERIMENTAL CELL RESEARCH (2002)
Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1
T Pierson et al.
JOURNAL OF VIROLOGY (2000)
Share Paper
